^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD38 positive

    i
    Other names: CD38, CD38 Molecule, ADP-Ribosyl Cyclase 1, ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1, 2'-Phospho-Cyclic-ADP-Ribose Transferase, 2'-Phospho-ADP-Ribosyl Cyclase, Cyclic ADP-Ribose Hydrolase 1, NAD(+) Nucleosidase, CD38 Antigen (P45), ADPRC 1, 2'-Phospho-ADP-Ribosyl Cyclase/2'-Phospho-Cyclic-ADP-Ribose Transferase, Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase, Cluster Of Differentiation 38, CADPr Hydrolase 1, CD38 Antigen, ADPRC1, T10
    Entrez ID:
    952
    Related biomarkers:
    Expression
    Others
    Apply
    Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT01243190)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    09/19/2024
    Initiation :
    03/01/2011
    Primary completion :
    03/28/2023
    Completion :
    03/28/2023
    IGH • CD38
    |
    CD38 positive
    |
    Arzerra (ofatumumab)
    A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT04177823)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    04/19/2024
    Initiation :
    12/09/2019
    Primary completion :
    12/30/2022
    Completion :
    12/30/2022
    CD8
    |
    CD38 positive
    |
    Blenrep (belantamab mafodotin-blmf)
    A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (CARLOTTA01) (NCT05836896)
    Phase 1
    Technische Universität Dresden
    Recruiting
    Last update posted :
    02/20/2024
    Initiation :
    02/15/2024
    Primary completion :
    06/01/2025
    Completion :
    06/01/2026
    CD31 • SLAMF7
    |
    CD38 positive
    |
    MDC-CAR-BCMA001
    Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A (NCT03766763)
    Phase 2
    French Innovative Leukemia Organisation
    Recruiting
    Last update posted :
    07/27/2022
    Initiation :
    05/22/2019
    Primary completion :
    01/22/2022
    Completion :
    02/01/2028
    CD20 • CD200
    |
    CD20 positive • CD38 positive
    |
    Venclexta (venetoclax)
    Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) (NCT01276236)
    Phase 2
    University of California, San Francisco
    Completed
    Last update posted :
    03/05/2021
    Initiation :
    03/09/2011
    Primary completion :
    01/31/2015
    Completion :
    04/30/2015
    CD8 • CD38 • CD4 • CD69
    |
    CD38 positive • CD8 negative
    |
    Selzentry (maraviroc)